Literature DB >> 19300044

Current treatment for cutaneous leishmaniasis: a review.

Emilio Palumbo1.   

Abstract

Cutaneous leishmaniasis is the most common form of leishmaniasis. It is a skin infection caused by a single-celled parasite that is transmitted by sand fly bites. There are about 20 species of Leishmania that may cause cutaneous leishmaniasis. Some Leishmania species are closely linked to humans and are therefore found in cities (Leishmania tropica), whereas some are more traditionally associated with animal species and are therefore considered zoonoses (Leishmania major). The evidence for optimal treatment of cutaneous leishmaniasis is patchy. Although the cutaneous form of the disease is often self-limiting, it does result in significant scarring and can spread to more invasive, mucocutaneous disease. Therefore, treatment may be considered to prevent these complications. Drugs for systemic and topical treatment are presented and discussed with regard to their application, use, and adverse effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300044     DOI: 10.1097/MJT.0b013e3181822e90

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  17 in total

1.  Identification of new antileishmanial leads from hits obtained by high-throughput screening.

Authors:  Xiaohua Zhu; Trupti Pandharkar; Karl Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.

Authors:  Alex G Peniche; Yaneth Osorio; Adam R Renslo; Doug E Frantz; Peter C Melby; Bruno L Travi
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.

Authors:  Iván Vélez; Liliana López; Ximena Sánchez; Laureano Mestra; Carlos Rojas; Erwin Rodríguez
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

4.  Universal PCR assays for the differential detection of all Old World Leishmania species.

Authors:  S Ogado Ceasar Odiwuor; A Ageed Saad; S De Doncker; I Maes; T Laurent; S El Safi; M Mbuchi; P Büscher; J-C Dujardin; G Van der Auwera
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-09       Impact factor: 3.267

5.  Effect of elatol, isolated from red seaweed Laurencia dendroidea, on Leishmania amazonensis.

Authors:  Adriana Oliveira Dos Santos; Phercyles Veiga-Santos; Tânia Ueda-Nakamura; Benedito Prado Dias Filho; Daniela Bueno Sudatti; Everson Miguel Bianco; Renato Crespo Pereira; Celso Vataru Nakamura
Journal:  Mar Drugs       Date:  2010-10-29       Impact factor: 5.118

6.  Leishmania life cycle images in the cutaneous cytologic smear of an immunocompetent patient.

Authors:  Roberta Zappacosta; Roberta Claudi; Salvatore Magnasco; Emma Dell'osa
Journal:  J Cytol       Date:  2010-01       Impact factor: 1.000

7.  Protein network prediction and topological analysis in Leishmania major as a tool for drug target selection.

Authors:  Andrés F Flórez; Daeui Park; Jong Bhak; Byoung-Chul Kim; Allan Kuchinsky; John H Morris; Jairo Espinosa; Carlos Muskus
Journal:  BMC Bioinformatics       Date:  2010-09-27       Impact factor: 3.169

8.  Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani.

Authors:  Sushma Singh; Neeradi Dinesh; Preet Kamal Kaur; Baigadda Shamiulla
Journal:  Parasitol Res       Date:  2014-04-12       Impact factor: 2.289

9.  New world cutaneous leishmaniasis treated with intralesional injection of pentavalent antimony.

Authors:  Ji Yeon Shin; Young Bok Lee; Baik Kee Cho; Hyun Jeong Park
Journal:  Ann Dermatol       Date:  2013-02-14       Impact factor: 1.444

10.  Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.

Authors:  Liliana López; Martha Robayo; Margarita Vargas; Iván D Vélez
Journal:  Trials       Date:  2012-05-17       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.